Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Aaron Seth Kesselheim, M.D.

TitleAssistant Professor of Medicine
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressHarvard School of Public Health
Kresge Bldg Suite 432
677 Huntington Ave
Boston MA 02115
Phone617/732-5775
Fax617/732-7072

 Mentoring 
 current student opportunities
Medical Device Policy[login at prompt]
Available: 03/01/14, Expires: 08/01/14

Projects evaluating the regulatory approach to medical devices, trade-offs between patient access to technology and effectiveness data, strategies for post-market surveillance.

 completed student projects
FDA Premarket Approval Supplements and Medical Device Safety and Effectiveness
Summer, 03/01/13 - 12/21/13
Clinical and Regulatory Features of Drugs Not Initially Approved by the US Food and Drug Administration
Full Time/Year Long, 05/01/13 - 04/30/14
Technological innovations in medication packaging to improve patient adherence: a systematic review
Summer, 06/11/12 - 08/10/12
Clinical Equivalence of Generic and Brand-Name Drugs in Cardiovascular Disease: A Systematic Review and Meta-Analysis
Summer, 12/10/07 - 10/19/08
Promoting Medical Innovation: The Case of Coronary Artery Stents
Summer, 06/13/11 - 08/31/11

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Kesselheim AS, Shiu N. The evolving role of biomarker patents in personalized medicine. Clin Pharmacol Ther. 2014 Feb; 95(2):127-9.
    View in: PubMed
  2. Hwang TJ, Carpenter D, Kesselheim AS. Assessment of US pathway for approving medical devices for rare conditions. BMJ. 2014; 348:g217.
    View in: PubMed
  3. Rome BN, Kramer DB, Kesselheim AS. FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012. JAMA. 2014 Jan 22-29; 311(4):385-91.
    View in: PubMed
  4. Kesselheim AS, Avorn J. New and unproved medical devices. BMJ. 2013; 347:f7413.
    View in: PubMed
  5. Shah AK, Warsh J, Kesselheim AS. The ethics of intellectual property rights in an era of globalization. J Law Med Ethics. 2013 Dec; 41(4):841-51.
    View in: PubMed
  6. Yeh JS, Kesselheim AS. Same song, different audience: pharmaceutical promotion targeting non-physician health care providers. PLoS Med. 2013 Nov; 10(11):e1001560.
    View in: PubMed
  7. Wang B, Kesselheim AS. The Role of Direct-to-Consumer Pharmaceutical Advertising in Patient Consumerism. Virtual Mentor. 2013; 15(11):960-5.
    View in: PubMed
  8. Austad KE, Avorn J, Franklin JM, Kesselheim AS. Physician trainees' interactions with the pharmaceutical industry. J Gen Intern Med. 2013 Oct; 28(10):1267.
    View in: PubMed
  9. Kramer DB, Tan YT, Sato C, Kesselheim AS. Postmarket Surveillance of Medical Devices: A Comparison of Strategies in the US, EU, Japan, and China. PLoS Med. 2013 Sep; 10(9):e1001519.
    View in: PubMed
  10. Kesselheim AS, Green MD, Avorn J. Who is now responsible for discovering and warning about adverse effects of generic drugs? JAMA. 2013 Sep 11; 310(10):1023-4.
    View in: PubMed
  11. Kramer DB, Kesselheim AS. The medical device excise tax--before it begins? N Engl J Med. 2013 Sep 5; 369(10):984-5.
    View in: PubMed
  12. Gagne JJ, Polinski JM, Kesselheim AS, Choudhry NK, Hutchins D, Matlin OS, Tong A, Shrank WH. Patterns and predictors of generic narrow therapeutic index drug use among older adults. J Am Geriatr Soc. 2013 Sep; 61(9):1586-91.
    View in: PubMed
  13. Outterson K, Powers JH, Seoane-Vazquez E, Rodriguez-Monguio R, Kesselheim AS. Approval and withdrawal of new antibiotics and other antiinfectives in the u.s., 1980-2009. J Law Med Ethics. 2013 Sep; 41(3):688-96.
    View in: PubMed
  14. Ross JS, Kesselheim AS. Prescription-drug coupons--no such thing as a free lunch. N Engl J Med. 2013 Sep 26; 369(13):1188-9.
    View in: PubMed
  15. Wang B, Avorn J, Kesselheim AS. Clinical and regulatory features of drugs not initially approved by the FDA. Clin Pharmacol Ther. 2013 Dec; 94(6):670-7.
    View in: PubMed
  16. Austad KE, Avorn J, Franklin JM, Kowal MK, Campbell EG, Kesselheim AS. Erratum to: Changing Interactions Between Physician Trainees and the Pharmaceutical Industry: A National Survey. J Gen Intern Med. 2013 Aug; 28(8):1115-6.
    View in: PubMed
  17. Austad KE, Avorn J, Franklin JM, Kowal MK, Campbell EG, Kesselheim AS. Changing interactions between physician trainees and the pharmaceutical industry: a national survey. J Gen Intern Med. 2013 Aug; 28(8):1064-71.
    View in: PubMed
  18. Rajkumar R, Kesselheim AS. Balancing access and innovation: India's Supreme Court rules on imatinib. JAMA. 2013 Jul 17; 310(3):263-4.
    View in: PubMed
  19. Kesselheim AS, Cook-Deegan RM, Winickoff DE, Mello MM. Gene patenting--the Supreme Court finally speaks. N Engl J Med. 2013 Aug 29; 369(9):869-75.
    View in: PubMed
  20. Kesselheim AS. Rising health care costs and life-cycle management in the pharmaceutical market. PLoS Med. 2013 Jun; 10(6):e1001461.
    View in: PubMed
  21. Kesselheim AS, Wang B, Avorn J. Defining "innovativeness" in drug development: a systematic review. Clin Pharmacol Ther. 2013 Sep; 94(3):336-48.
    View in: PubMed
  22. Kesselheim AS, Avorn J. The most transformative drugs of the past 25 years: a survey of physicians. Nat Rev Drug Discov. 2013 May; 12(6):425-31.
    View in: PubMed
  23. Kesselheim AS, Robertson CT, Siri K, Batra P, Franklin JM. Distributions of industry payments to Massachusetts physicians. N Engl J Med. 2013 May 30; 368(22):2049-52.
    View in: PubMed
  24. Kesselheim AS, Franklin JM, Avorn J, Duke JD. Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs. BMJ Qual Saf. 2013 Sep; 22(9):727-34.
    View in: PubMed
  25. Kramer DB, Kesselheim AS. The medical device excise tax--over before it begins? N Engl J Med. 2013 May 9; 368(19):1767-9.
    View in: PubMed
  26. Kesselheim AS. Drug company gifts to medical students: the hidden curriculum. BMJ. 2013; 346:f1113.
    View in: PubMed
  27. Kesselheim AS, Misono AS, Shrank WH, Greene JA, Doherty M, Avorn J, Choudhry NK. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med. 2013 Feb 11; 173(3):202-8.
    View in: PubMed
  28. Kesselheim AS, Mello MM, Avorn J. FDA regulation of off-label drug promotion under attack. JAMA. 2013 Feb 6; 309(5):445-6.
    View in: PubMed
  29. Kesselheim AS, Avorn J, Greene JA. Risk, responsibility, and generic drugs. N Engl J Med. 2012 Nov; 367(18):1679-81.
    View in: PubMed
  30. Xu S, Avorn J, Kesselheim AS. Origins of medical innovation: the case of coronary artery stents. Circ Cardiovasc Qual Outcomes. 2012 Nov 1; 5(6):743-9.
    View in: PubMed
  31. Kesselheim AS, Avorn J. Drug labels: a flawed source of data for studying orphan drug approvals. Clin Pharmacol Ther. 2012 Dec; 92(6):694.
    View in: PubMed
  32. Kramer DB, Kesselheim AS. User fees and beyond--the FDA Safety and Innovation Act of 2012. N Engl J Med. 2012 Oct 4; 367(14):1277-9.
    View in: PubMed
  33. Kesselheim AS, Avorn J. The Food and Drug Administration has the legal basis to restrict promotion of flawed comparative effectiveness research. Health Aff (Millwood). 2012 Oct; 31(10):2200-5.
    View in: PubMed
  34. Amin T, Kesselheim AS. Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades. Health Aff (Millwood). 2012 Oct; 31(10):2286-94.
    View in: PubMed
  35. Kesselheim AS, Robertson CT, Myers JA, Rose SL, Gillet V, Ross KM, Glynn RJ, Joffe S, Avorn J. A randomized study of how physicians interpret research funding disclosures. N Engl J Med. 2012 Sep 20; 367(12):1119-27.
    View in: PubMed
  36. Greene JA, Choudhry NK, Kesselheim AS, Brennan TA, Shrank W. Changes in direct-to-consumer pharmaceutical advertising following shifts from prescription-only to over-the-counter status. JAMA. 2012 Sep 12; 308(10):973-5.
    View in: PubMed
  37. Robertson C, Rose S, Kesselheim AS. Effect of financial relationships on the behaviors of health care professionals: a review of the evidence. J Law Med Ethics. 2012 Sep; 40(3):452-66.
    View in: PubMed
  38. Kesselheim AS, Orentlicher D. INTRODUCTION: Insights from a National Conference: "Conflicts of Interest in the Practice of Medicine". J Law Med Ethics. 2012 Sep; 40(3):436-40.
    View in: PubMed
  39. Kesselheim AS, Wang B, Studdert DM, Avorn J. Conflict of interest reporting by authors involved in promotion of off-label drug use: an analysis of journal disclosures. PLoS Med. 2012; 9(8):e1001280.
    View in: PubMed
  40. Kesselheim AS. Ethical considerations in orphan drug approval and use. Clin Pharmacol Ther. 2012 Aug; 92(2):153-5.
    View in: PubMed
  41. Kramer DB, Xu S, Kesselheim AS. How does medical device regulation perform in the United States and the European union? A systematic review. PLoS Med. 2012; 9(7):e1001276.
    View in: PubMed
  42. Truog RD, Kesselheim AS, Joffe S. Research ethics. Paying patients for their tissue: the legacy of Henrietta Lacks. Science. 2012 Jul 6; 337(6090):37-8.
    View in: PubMed
  43. Kesselheim AS, Karlawish J. Biomarkers unbound--the Supreme Court's ruling on diagnostic-test patents. N Engl J Med. 2012 Jun 21; 366(25):2338-40.
    View in: PubMed
  44. Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One. 2012; 7(2):e31894.
    View in: PubMed
  45. Kramer DB, Xu S, Kesselheim AS. Regulation of medical devices in the United States and European Union. N Engl J Med. 2012 Mar 1; 366(9):848-55.
    View in: PubMed
  46. Cole LW, Kesselheim JC, Kesselheim AS. Ethical issues in new drug prescribing. J Bioeth Inq. 2012 Mar; 9(1):77-83.
    View in: PubMed
  47. Kesselheim AS, Darby D, Studdert DM, Glynn R, Levin R, Avorn J. False Claims Act prosecution did not deter off-label drug use in the case of neurontin. Health Aff (Millwood). 2011 Dec; 30(12):2318-27.
    View in: PubMed
  48. Kesselheim AS, Cresswell K, Phansalkar S, Bates DW, Sheikh A. Clinical decision support systems could be modified to reduce 'alert fatigue' while still minimizing the risk of litigation. Health Aff (Millwood). 2011 Dec; 30(12):2310-7.
    View in: PubMed
  49. Avorn J, Kesselheim AS. The NIH translational research center might trade public risk for private reward. Nat Med. 2011 Oct; 17(10):1176.
    View in: PubMed
  50. Kesselheim AS, Murtagh L, Mello MM. "Pay for delay" settlements of disputes over pharmaceutical patents. N Engl J Med. 2011 Oct 13; 365(15):1439-45.
    View in: PubMed
  51. Austad KE, Kesselheim AS. Conflict of interest disclosure in early education of medical students. JAMA. 2011 Sep 7; 306(9):991-2.
    View in: PubMed
  52. Kesselheim AS. An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences. Milbank Q. 2011 Sep; 89(3):450-502.
    View in: PubMed
  53. Kesselheim AS, Rajkumar R. Who owns federally funded research? The Supreme court and the Bayh-Dole act. N Engl J Med. 2011 Sep 29; 365(13):1167-9.
    View in: PubMed
  54. Kesselheim AS. The backlash against bioequivalence and the interchangeability of brand-name and generic drugs. CMAJ. 2011 Sep 6; 183(12):1350-1.
    View in: PubMed
  55. Greene JA, Kesselheim AS. Why do the same drugs look different? Pills, trade dress, and public health. N Engl J Med. 2011 Jul 7; 365(1):83-9.
    View in: PubMed
  56. Kesselheim AS, Lee JL, Avorn J, Servi A, Shrank WH, Choudhry NK. Conflict of interest in oncology publications: a survey of disclosure policies and statements. Cancer. 2012 Jan 1; 118(1):188-95.
    View in: PubMed
  57. Carpenter D, Kesselheim AS, Joffe S. Reputation and precedent in the bevacizumab decision. N Engl J Med. 2011 Jul 14; 365(2):e3.
    View in: PubMed
  58. Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA. 2011 Jun 8; 305(22):2320-6.
    View in: PubMed
  59. Austad KE, Avorn J, Kesselheim AS. Medical students' exposure to and attitudes about the pharmaceutical industry: a systematic review. PLoS Med. 2011 May; 8(5):e1001037.
    View in: PubMed
  60. Kesselheim A. Safety, supply, and suits--litigation and the vaccine industry. N Engl J Med. 2011 Apr 21; 364(16):1485-7.
    View in: PubMed
  61. Avorn J, Kesselheim A. A hemorrhage of off-label use. Ann Intern Med. 2011 Apr 19; 154(8):566-7.
    View in: PubMed
  62. Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med. 2011 Apr; 8(4):e1000431.
    View in: PubMed
  63. Shrank WH, Liberman JN, Fischer MA, Avorn J, Kilabuk E, Chang A, Kesselheim AS, Brennan TA, Choudhry NK. The consequences of requesting "dispense as written". Am J Med. 2011 Apr; 124(4):309-17.
    View in: PubMed
  64. Kesselheim AS. Covert pharmaceutical promotion in free medical journals. CMAJ. 2011 Mar 22; 183(5):534-5.
    View in: PubMed
  65. Kramer DB, Kesselheim AS, Salberg L, Brock DW, Maisel WH. Ethical and legal views regarding deactivation of cardiac implantable electrical devices in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2011 Apr 1; 107(7):1071-1075.e5.
    View in: PubMed
  66. Kesselheim AS, Austad KE. Residents: workers or students in the eyes of the law? N Engl J Med. 2011 Feb 24; 364(8):697-9.
    View in: PubMed
  67. Kesselheim AS. Off-label drug use and promotion: balancing public health goals and commercial speech. Am J Law Med. 2011; 37(2-3):225-57.
    View in: PubMed
  68. Kesselheim AS, Outterson K. Improving antibiotic markets for long-term sustainability. Yale J Health Policy Law Ethics. 2011; 11(1):101-67.
    View in: PubMed
  69. Polinski JM, Kesselheim AS. Where cost, medical necessity, and morality meet: should US government insurance programs pay for erectile dysfunction drugs? Clin Pharmacol Ther. 2011 Jan; 89(1):17-9.
    View in: PubMed
  70. Kesselheim AS. Adalimumab pricing and market exclusivity for biologics. N Engl J Med. 2010 Dec 9; 363(24):2374.
    View in: PubMed
  71. Greene JA, Kesselheim AS. Pharmaceutical marketing and the new social media. N Engl J Med. 2010 Nov 25; 363(22):2087-9.
    View in: PubMed
  72. Cutler C, Kesselheim A, Gabardi S, Andersson BS, Carpenter P, Khoury HJ, Litzow M, Rowley SD, Lanum S, Leather H, Tina Shih YC, Gale RP, Wingard JR, Appelbaum FR, Anasetti C. Generic immunosuppressants in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011 Mar; 17(3):285-90.
    View in: PubMed
  73. Kesselheim AS. Using market-exclusivity incentives to promote pharmaceutical innovation. N Engl J Med. 2010 Nov 4; 363(19):1855-62.
    View in: PubMed
  74. Chokshi DA, Avorn J, Kesselheim AS. Designing comparative effectiveness research on prescription drugs: lessons from the clinical trial literature. Health Aff (Millwood). 2010 Oct; 29(10):1842-8.
    View in: PubMed
  75. Outterson K, Powers JH, Gould IM, Kesselheim AS. Questions about the 10 x '20 Initiative. Clin Infect Dis. 2010 Sep 15; 51(6):751-2; author reply 754-5.
    View in: PubMed
  76. Kesselheim AS, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff (Millwood). 2010 Sep; 29(9):1689-96.
    View in: PubMed
  77. Kramer DB, Kesselheim AS, Brock DW, Maisel WH. Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessment. Heart Rhythm. 2010 Nov; 7(11):1537-42.
    View in: PubMed
  78. Shrank WH, Choudhry NK, Agnew-Blais J, Federman AD, Liberman JN, Liu J, Kesselheim AS, Brookhart MA, Fischer MA. State generic substitution laws can lower drug outlays under Medicaid. Health Aff (Millwood). 2010 Jul; 29(7):1383-90.
    View in: PubMed
  79. Kesselheim AS, Maisel WH. Managing financial and nonfinancial conflicts of interest in healthcare delivery. Am J Ther. 2010 Jul-Aug; 17(4):440-3.
    View in: PubMed
  80. Kesselheim AS. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety. Clin Pharmacol Ther. 2010 Jun; 87(6):645-7.
    View in: PubMed
  81. Kesselheim AS, Studdert DM, Mello MM. Whistle-blowers' experiences in fraud litigation against pharmaceutical companies. N Engl J Med. 2010 May 13; 362(19):1832-9.
    View in: PubMed
  82. Kesselheim AS, November MT, Lifford KL, McElrath TF, Puopolo AL, Orav EJ, Studdert DM. Using malpractice claims to identify risk factors for neurological impairment among infants following non-reassuring fetal heart rate patterns during labour. J Eval Clin Pract. 2010 Jun; 16(3):476-83.
    View in: PubMed
  83. Kesselheim AS, Solomon DH. Incentives for drug development--the curious case of colchicine. N Engl J Med. 2010 Jun 3; 362(22):2045-7.
    View in: PubMed
  84. Kesselheim AS, Mello MM. Gene patenting--is the pendulum swinging back? N Engl J Med. 2010 May 20; 362(20):1855-8.
    View in: PubMed
  85. Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, Brookhart MA, Avorn J, Shrank WH. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs. 2010 Mar 26; 70(5):605-21.
    View in: PubMed
  86. Wheadon DE. Market exclusivity for biologics. N Engl J Med. 2010 Feb 18; 362(7):661; author reply 661-2.
    View in: PubMed
  87. Stedman MR, Curtin F, Elbourne DR, Kesselheim AS, Brookhart MA. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol. 2011 Dec; 40(6):1732-4.
    View in: PubMed
  88. Kesselheim AS. The Supreme Court, process patents, and medical innovation. N Engl J Med. 2009 Dec 10; 361(24):2303-6.
    View in: PubMed
  89. Engelberg AB, Kesselheim AS, Avorn J. Balancing innovation, access, and profits--market exclusivity for biologics. N Engl J Med. 2009 Nov 12; 361(20):1917-9.
    View in: PubMed
  90. Amin T, Rajkumar R, Radhakrishnan P, Kesselheim AS. Expert review of drug patent applications: improving health in the developing world. Health Aff (Millwood). 2009 Sep-Oct; 28(5):w948-56.
    View in: PubMed
  91. Outterson K, Kesselheim AS. How Medicare could get better prices on prescription drugs. Health Aff (Millwood). 2009 Sep-Oct; 28(5):w832-41.
    View in: PubMed
  92. Kesselheim AS. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development. Clin Pharmacol Ther. 2009 Jun; 85(6):573-5.
    View in: PubMed
  93. Kesselheim AS, Studdert DM. The Supreme Court, preemption, and malpractice liability. N Engl J Med. 2009 Feb 5; 360(6):559-61.
    View in: PubMed
  94. Kesselheim AS, Avorn J. Using patent data to assess the value of pharmaceutical innovation. J Law Med Ethics. 2009; 37(2):176-83.
    View in: PubMed
  95. Kesselheim AS, Studdert DM. Professional oversight of physician expert witnesses: an analysis of complaints to the Professional Conduct Committee of the American Association of Neurological Surgeons, 1992-2006. Ann Surg. 2009 Jan; 249(1):168-72.
    View in: PubMed
  96. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008 Dec 3; 300(21):2514-26.
    View in: PubMed
  97. Kesselheim AS. Drug development for neglected diseases - the trouble with FDA review vouchers. N Engl J Med. 2008 Nov 6; 359(19):1981-3.
    View in: PubMed
  98. Kesselheim AS, Studdert DM. Whistleblower-initiated enforcement actions against health care fraud and abuse in the United States, 1996 to 2005. Ann Intern Med. 2008 Sep 2; 149(5):342-9.
    View in: PubMed
  99. Kesselheim AS, Avorn J. Pharmaceutical promotion to physicians and First Amendment rights. N Engl J Med. 2008 Apr 17; 358(16):1727-32.
    View in: PubMed
  100. Kesselheim AS, Choudhry NK. The international pharmaceutical market as a source of low-cost prescription drugs for U.S. patients. Ann Intern Med. 2008 Apr 15; 148(8):614-9.
    View in: PubMed
  101. Chokshi DA, Kesselheim AS. Rethinking global access to vaccines. BMJ. 2008 Apr 5; 336(7647):750-3.
    View in: PubMed
  102. Dudzinski DM, Kesselheim AS. Scientific and legal viability of follow-on protein drugs. N Engl J Med. 2008 Feb 21; 358(8):843-9.
    View in: PubMed
  103. Kesselheim AS. Think globally, prescribe locally: how rational pharmaceutical policy in the U.S. can improve global access to essential medicines. Am J Law Med. 2008; 34(2-3):125-39.
    View in: PubMed
  104. Outterson K, Kesselheim AS. Market-based licensing for HPV vaccines in developing countries. Health Aff (Millwood). 2008 Jan-Feb; 27(1):130-9.
    View in: PubMed
  105. Kesselheim AS, Studdert DM. Role of professional organizations in regulating physician expert witness testimony. JAMA. 2007 Dec 26; 298(24):2907-9.
    View in: PubMed
  106. Shrank WH, Agnew-Blais J, Choudhry NK, Wolf MS, Kesselheim AS, Avorn J, Shekelle P. The variability and quality of medication container labels. Arch Intern Med. 2007 Sep 10; 167(16):1760-5.
    View in: PubMed
  107. Kesselheim AS. Intellectual property policy in the pharmaceutical sciences: the effect of inappropriate patents and market exclusivity extensions on the health care system. AAPS J. 2007; 9(3):E306-11.
    View in: PubMed
  108. Kesselheim AS and Mello MM. Confidentiality laws and secrecy in medical research: improving access to drug safety data. Health Affairs. 2007; 26(2):483-491.
  109. Kesselheim AS, Mello MM. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety. Health Aff (Millwood). 2007 Mar-Apr; 26(2):483-91.
    View in: PubMed
  110. Kesselheim AS and Avorn J. The role of litigation in drug safety. Journal of the American Medical Association. 2007; 297(3):308-311.
  111. Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA. 2007 Jan 17; 297(3):308-11.
    View in: PubMed
  112. Kesselheim AS and Avorn J. [Textbook chapter] In: Springer Science; 2007 (in press). Patents and public health. Galea S, ed. Macrosocial Determinants of Health. 2007.
  113. Kesselheim AS and Studdert DM. Author Reply: Characteristics of physicians who frequently act as expert witnesses in neurological birth injury litigation. Obstetrics & Gynecology. 2006; 108(6):1552-1553.
  114. Kesselheim AS, Mello MM. Medical process patents – monopolizing the delivery of health care. New England Journal of Medicine. 2006; 355(19):2036-2041.
  115. Kesselheim AS, Mello MM. Medical-process patents--monopolizing the delivery of health care. N Engl J Med. 2006 Nov 9; 355(19):2036-41.
    View in: PubMed
  116. Kesselheim AS, Fischer MA, Avorn J. Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending. Health Aff (Millwood). 2006 Nov-Dec; 25(6):1637-47.
    View in: PubMed
  117. Kesselheim AS, Fischer MA, Avorn J. Extensions of intellectual property rights and delayed adoption of generic drugs: effects on Medicaid spending. Health Affairs. 2006; 25(6):1637-1647.
  118. Reese PP, Caplan AL, Kesselheim AS, Bloom RD. Creating a medical, ethical, and legal framework for complex living kidney donors. Clin J Am Soc Nephrol. 2006 Nov; 1(6):1148-53.
    View in: PubMed
  119. Kesselheim AS and Studdert DM. Author Reply: Clinical performance measures and medical malpractice. Journal of the American Medical Association. 2006; 296(13):1589-1590.
  120. Kesselheim AS, Studdert DM. Characteristics of physicians who frequently act as expert witnesses in neurologic birth injury litigation. Obstet Gynecol. 2006 Aug; 108(2):273-9.
    View in: PubMed
  121. Kesselheim AS and Studdert DM. Characteristics of physicians who frequently act as expert witnesses in neurological birth injury litigation. Obstetrics & Gynecology. 2006; 108(2):273-279.
  122. Kesselheim AS, Fischer MA, Avorn J. The rise and fall of Natrecor for congestive heart failure: implications for drug policy. Health Affairs. 2006; 25(4):1095-1102.
  123. Kesselheim AS, Fischer MA, Avorn J. The rise and fall of Natrecor for congestive heart failure: implications for drug policy. Health Aff (Millwood). 2006 Jul-Aug; 25(4):1095-102.
    View in: PubMed
  124. Kesselheim AS, Ferris TG, Studdert DM. Will physician-level measures of clinical performance be used in medical malpractice litigation? JAMA. 2006 Apr 19; 295(15):1831-4.
    View in: PubMed
  125. Kesselheim AS, Avorn J. Biomedical patents and the public's health: is there a role for eminent domain? JAMA. 2006 Jan 25; 295(4):434-7.
    View in: PubMed
  126. Kesselheim AS and Avorn J. Biomedical patents and the public’s health: is there a role for eminent domain?. Journal of the American Medical Association. 2006; 295(4):434-437.
  127. Rudnick MR, Kesselheim A, Goldfarb S. Contrast-induced nephropathy: how it develops, how to prevent it. Cleve Clin J Med. 2006 Jan; 73(1):75-80, 83-7.
    View in: PubMed
  128. Friedberg MA and Kesselheim AS. Establishing a medico-legal and health policy education curriculum for medical residents. Journal of General Internal Medicine. 2006; 21 suppl. 4:172.
  129. Kesselheim AS and Avorn J. Biotechnology products and university-based science. Journal of the American Medical Association. 2005; 293(23):2863.
  130. Kesselheim AS and Brennan TA. Overbilling vs. downcoding — the battle between physicians and insurers. New England Journal of Medicine. 2005; 352(9):855-857.
  131. Kesselheim AS, Brennan TA. Overbilling vs. downcoding--the battle between physicians and insurers. N Engl J Med. 2005 Mar 3; 352(9):855-7.
    View in: PubMed
  132. Kesselheim AS, Avorn J. University-based science and biotechnology products: defining the boundaries of intellectual property. JAMA. 2005 Feb 16; 293(7):850-4.
    View in: PubMed
  133. Kesselheim AS and Avorn J. University-based science and biotechnology research: defining the boundaries of intellectual property. Journal of the American Medical Association. 2005; 293(7):850-854.
  134. Kesselheim AS, Stevenson LW, Nohria A, Fischer MA, Avorn J. Assessing patients with decompensated CHF. Brigham and Women’s Hospital medication use guidelines. 2005.
  135. Kesselheim AS, Brennan TA. The swinging pendulum: the Supreme Court reverses course on ERISA and managed care. Yale J Health Policy Law Ethics. 2005; 5(1):451-63.
    View in: PubMed
  136. Kesselheim AS. Patents and intellectual property in medicine. Legal Medicine. 2004; 207-213.
  137. Kesselheim AS. Perspectives: ode to a short white coat. Pharos. 2003; 66:35.
  138. Kesselheim AS. Privacy versus the public's right to know. Presidential health and the White House physician. J Leg Med. 2002 Dec; 23(4):523-45.
    View in: PubMed
  139. Kesselheim AS. Privacy versus the public’s right to know: presidential health and the white house physician. Journal of Legal Medicine. 2002; 23(4):523-545.
  140. Kissick WL and Kesselheim AS. Presidential disability: the panel of physicians. Transactions & Studies of the College of Physicians of Philadelphia. 2001; 23:113-119.
  141. Kissick WL, Kesselheim AS. Final report of the college's presidential health task force. Trans Stud Coll Physicians Phila. 2001 Dec; 23:113-9.
    View in: PubMed
  142. Kesselheim AS. Deception and presidential disability: an historical analysis. Trans Stud Coll Physicians Phila. 2001 Dec; 23:87-98.
    View in: PubMed
  143. Kesselheim AS. Ensuring quality end-of-life cancer care: an analysis of the current state of patient and family information about end-of-life care issues, its deficiencies, and recommendations for the future. Gelband H & Foley KM, eds. Excellent end-of-life care for cancer patients: a policy agenda for action and research. 2001; 132-152.
  144. Kesselheim AS. What’s the appeal? Trying to control managed care medical necessity decisionmaking through a system of external appeals. University of Pennsylvania Law Review. 2001; 149(3):873-920.
  145. Treat J, Zrada S, Kesselheim AS, Walker S, Jenkins M, Gokhale P, Rahman A. A phase I trial in advanced malignancies with liposome encapsulated paclitaxel (LEP). Proceedings of ASCO. 1999; 18:230a.
  146. Kesselheim AS. A method to their madness: Greek methodism in its social context. 1996.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Kesselheim's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_